News

Leap will retain exclusive rights for the development, manufacturing, and commercialization of DKN-01 for the rest of the world. In addition, Leap announced entering into an agreement for

Dysport, an injectable form of a botulinum neurotoxin type A product, is a substance derived from Clostridium bacteria producing botulinum toxin type A (BoNT-A), which blocks the effective

BeiGene is a commercial-stage oncology firm focused on developing molecularly targeted and immuno-oncology drug candidates for the treatment of cancer. Former Amgen global commercial operations executive vice president

Under the terms of the transaction agreement, GSK has received an upfront payment of €308m ($345m) and Bavarian Nordic is expected to pay a total of up to

As part of the collaboration and licence agreement, the companies will work together to detect small molecules designed to modulate specific pathways linked with a targeted indication within

The US regulator has approved Lynparza as a maintenance treatment for adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma (pancreatic cancer) whose disease

The clinical program, which will be co-funded by the companies, is expected to include three phase 3 pivotal trials in advanced non-small cell lung cancer (NSCLC), castration-resistant prostate

Achillion continues to expect the transaction to close in the first half of 2020, subject to expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust

Kadcyla will be used to treat the patients who have residual invasive disease in the breast and/or lymph nodes after neoadjuvant (before surgery) taxane-based and HER2-targeted therapy. Kadcyla